Crispr Theraptc (NASDAQ:CRSP) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 998,670 shares, a growth of 60.7% from the October 13th total of 621,347 shares. Approximately 8.7% of the shares of the company are sold short. Based on an average trading volume of 210,975 shares, the days-to-cover ratio is presently 4.7 days.
In other Crispr Theraptc news, insider Samarth Kulkarni sold 27,154 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total transaction of $545,252.32. Following the sale, the insider now directly owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kurt Von Emster sold 3,150 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $18.52, for a total transaction of $58,338.00. The disclosure for this sale can be found here. Insiders have sold 253,350 shares of company stock worth $5,039,357 over the last ninety days. Insiders own 39.98% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the period. Capital Investment Advisory Services LLC bought a new position in shares of Crispr Theraptc in the third quarter valued at about $193,000. Ark Investment Management LLC bought a new position in shares of Crispr Theraptc in the second quarter valued at about $206,000. Moloney Securities Asset Management LLC bought a new position in shares of Crispr Theraptc in the third quarter valued at about $235,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Crispr Theraptc in the third quarter valued at about $288,000. 25.61% of the stock is currently owned by institutional investors.
Several analysts have issued reports on CRSP shares. Cann reaffirmed a “hold” rating on shares of Crispr Theraptc in a research report on Thursday, November 9th. Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. SunTrust Banks, Inc. reaffirmed a “hold” rating and set a $16.00 price target on shares of Crispr Theraptc in a research report on Friday, November 10th. Finally, Barclays PLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Crispr Theraptc in a research report on Friday, September 8th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Crispr Theraptc has an average rating of “Buy” and an average price target of $22.38.
Crispr Theraptc (NASDAQ CRSP) opened at $17.66 on Thursday. Crispr Theraptc has a 1 year low of $11.63 and a 1 year high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Theraptc had a negative net margin of 466.58% and a negative return on equity of 38.42%. Crispr Theraptc’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.77) earnings per share. sell-side analysts expect that Crispr Theraptc will post -2.46 earnings per share for the current fiscal year.
WARNING: “Crispr Theraptc (CRSP) Sees Significant Increase in Short Interest” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/16/crispr-theraptc-crsp-sees-significant-increase-in-short-interest.html.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.